Category: Portfolio Updates

Weekly Update

Weekly Market Overview – May 18-24, 2026

Tech strength supports markets, but robust US data fuels renewed interest rate concerns and weighs on renewable energy. Learn everything
Next Update
Revolution Medicines
Company Update

Revolution Medicines Update: FDA Breakthrough Therapy designation expands RASONQUE’s potential

Revolution Medicines receives another FDA Breakthrough Therapy designation for RASONQUE.
Next Update
Market Commentary

UMBRELLA Strategy: Inflation and Interest Rates Move the Markets

Inflation, oil prices, and interest rates are shaping the markets. In the UMBRELLA Strategy, tech stocks come under pressure while
Next Update
Thales
Company Update

Bayer Update: Roundup Hearing Moves into Focus

Bayer moves into focus ahead of the Roundup hearing. The stock approaches EUR 50 while legal risks and technical levels
Next Update
PayPal
Company Update

PayPal: Stop-Loss Triggers Complete Exit

PayPal falls below the stop-loss. The UMBRELLA Strategy sells the position in full and moves the stock to the watchlist.
Next Update
Thales
Company Update

Thales: Stop-Loss Triggers Complete Exit

The Thales position was sold in full after a stop-loss. The stock moves to the UMBRELLA watchlist and remains under
Next Update
Revolution Medicines
Company Update

European Defense Stocks Under Pressure: How the UMBRELLA Strategy Reacts

European defense stocks are coming under pressure. How does the UMBRELLA Strategy react to weaker momentum, high valuations, and the
Next Update
Thales
Company Update

Thales: Valuation After the Price Recovery

Thales impresses with strong half-year results 2026, record order backlog, and positive growth prospects in the defense sector.
Next Update
Bayer
Company Update

Bayer: Valuation Update After the Latest Price Recovery

Bayer after the latest price recovery: new developments in legal risks, analyst expectations, and the technical picture complement the valuation.
Next Update
Thales
Company Update

Thales: Target Acquired – Launch Clearance for Thales?

Thales impresses with strong half-year results 2026, record order backlog, and positive growth prospects in the defense sector.
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: TKMS, Palantir, and SpaceX in focus

TKMS impresses with strong figures and a raised outlook, while Palantir remains highly valued after the AI rally, and SpaceX
Next Update
MUMAK SpotLight

MUMAK SpotLight of the week: Five stocks in focus

Eli Lilly, Rheinmetall, Bayer, Palantir, and Revolution Medicines impress with strong developments—but valuation, risks, and chart technicals remain decisive.
Next Update